CClinicalTrials.gg
CompletedNCT03653039TritubeUpdated Feb 29, 2024

Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy

An interventional study of Tritube and Standard enditracheal tube in Oral Neoplasm, Pharynx Cancer and Larynx Cancer, sponsored by Michael Seltz Kristensen. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by Michael Seltz Kristensen · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The investigators compare the ease of intubation between a new ultra-thin endotracheal tube, "Tritube", and a standard endotracheal tube in patients with predictors of difficult laryngoscopy. Furthermore the investigators compare the acceptance of leaving the Tritube in trachea after end of anaesthesia, with the use of a tube exchange catheter.

Read the detailed description

In patients scheduled for surgery and anaesthesia in the Head-/neck/ear/nose/throat -region the investigators compare the ease of tracheal intubation between a new ultra-thin endotracheal tube, "Tritube", and a standard endotracheal tube in patients with predictors of difficult laryngoscopy. The intubation is performed with an angulated video laryngoscope.

Furthermore the investigators compare the acceptance of leaving the Tritube in trachea after end of anaesthesia, with the use of a tube exchange catheter. The latter continues into the post-operative recovery-ward.

02

Conditions studied

  • Oral Neoplasm
  • Pharynx Cancer
  • Larynx Cancer
03

In context

Laryngeal Neoplasms

244 studies on the registry are indexed under Laryngeal Neoplasms; 63 are open to participants now.

This study's enrollment of 48 is close to the median of 44 across 181 interventional studies indexed under Laryngeal Neoplasms.

Browse Laryngeal Neoplasms studies →

Lead sponsor

This is the only study on the registry with Michael Seltz Kristensen as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients for anaesthesia for surgery in the Head-/neck/ear/nose/throat
  • planned for oral intubation with video-laryngoscopy
  • with risk factors for difficult direct laryngoscopy

Exclusion criteria

Exclusion Criteria:

  • Patient with increased secretions in the airway (Pneumonia, bronchitis, productive cough)
  • Patients planned for awake intubation
  • Patients where mask-ventilation is judged to could become impossible
  • Patients where access to the cricothyroid membrane is judged to be difficult or impossible
  • Patients in ASA (american Society of Anaesthesiologists) physical classification status >3
  • Patients who are scheduled for rapid sequence induction (RSI) due to risk of aspiration
  • Patients with stridor
  • Patients with hypoxemia (Saturation \< 90 % in room air)
  • Operation duration planned to > 2.5 hours
  • Patients with the need for a nerve-stimulation-tube during surgery
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Tritube

    Device: Tritube

  • Active comparator
    Standard endotracheal tube

    Device: Standard enditracheal tube

Interventions

  • DeviceTritube

    The ultra thin tribute is used used for the ventilation of the patients in this arm

  • DeviceStandard enditracheal tube

    A standard endotracheal tube is used used for the ventilation of the patients in this arm

06

What researchers measure

Primary outcomes

  1. Rate of Excellent intubation conditions

    Rate of Excellent intubation conditions judged on the scale excellent/good/fair/poor

    Time frame: 2 hours

Secondary outcomes

  1. The rate of interruption by the tube of the view to the vocal cords at any time, to such a degree that it disturbs the intubation

    Time frame: 2 hours

  2. The Intubation Difficulty Score (IDS)

    The intubation difficulty scale , range 0 to 7, 0 indicates easy intubation, 1 - 5 indicates slight difficulty, 5\< indicates moderate to major difficulty

    Time frame: 2 hours

  3. Time to intubated

    Time from the tube is advanced past the vocal cords until the cuff is inflated in the trachea

    Time frame: 2 hours

  4. Time to the patient becomes ventilated via the tube

    Time from the tube is advanced past the vocal cords until the cuff is inflated in the trachea and CO2 waveform is observed

    Time frame: 2 hours

  5. Number of intubation attempts

    one attempt is every-time the tube is advanced past the incisors

    Time frame: 2 hours

  6. The rate of succesful intubation with 60 seconds

    Time frame: 1 minute

  7. Number of remodellings of the stilette

    Time frame: 2 hours

  8. rate of use for "reverse loading" of the tube on the stylet

    Time frame: 2 hours

  9. the "percent of glottic opening" , (POGO), Before the tube is inserted

    Time frame: 2 hours

  10. the"percent of glottic opening" , POGO, with the tube in place

    Time frame: 2 hors

  11. Intubation conditions Strom scale

    Direction of the tube-stylet combination excellent/good/poor, easy/fair/difficult. Advancement of the tube-stylet combination excellent/good/poor easy/fair/difficult

    Time frame: 2 hours

  12. The surgeons score of the space and working conditions in the mouth/pharynx and larynx after intubation

    Time frame: 2 hours

  13. The difference between ET CO2 and arterial blood-gas CO2 after 15 minutes of surgery

    Time frame: 20 minutes

  14. the duration of the Tritube being in the trachea after return of spontaneous ventilation and deflation of the cuff /(Tritube group)

    Time frame: 4 hours

  15. The duration of the tube-exchange catheter being in the trachea after its placement / (Tube-exchange-catheter group)

    Time frame: 4 hours

  16. The ration of patients who still has the Tritube or the tube-exchange-catheter in place when arriving in the post-operative recovery unit

    Time frame: 4 hours

  17. The ration of patients who still has the Tritube or the tube-exchange-catheter in place one hour after arrival in the Post anaesthesia care unit the post-operative recovery unit

    Time frame: 4 hours

  18. The patient's satisfaction with having the Tritube or the tube-exchange-catheter in place when being awake in the Post anaesthesia care unit

    Visual analog scale from 1-10, 1= no nuisance, 10= unberable

    Time frame: 4 hours

07

Study locations

1 site
  • Rigshospitalet, section for anaesthesia for ENT and Maxillofacial surgery, section 3071
    Copenhagen, 2100, Denmark
08

References and documents

Publications

  • Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J; 8th International Neuromuscular Meeting. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007 Aug;51(7):789-808. doi: 10.1111/j.1399-6576.2007.01352.x. PubMed 17635389 ↗
  • Kristensen MS, de Wolf MWP, Rasmussen LS. Ventilation via the 2.4 mm internal diameter Tritube(R) with cuff - new possibilities in airway management. Acta Anaesthesiol Scand. 2017 Jul;61(6):580-589. doi: 10.1111/aas.12894. Epub 2017 Apr 23. PubMed 28436022 ↗
  • Strom C, Barnung S, Kristensen MS, Bottger M, Tvede MF, Rasmussen LS. Tracheal intubation in patients with anticipated difficult airway using Boedeker intubation forceps and McGrath videolaryngoscope. Acta Anaesthesiol Scand. 2015 Oct;59(9):1154-60. doi: 10.1111/aas.12543. Epub 2015 May 16. PubMed 25982220 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03653039
Lead sponsor
Michael Seltz Kristensen
Responsible party
Michael Seltz Kristensen (Principal Investigator, Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Aug 31, 2018
Start date
Sep 12, 2018
Primary completion
Feb 14, 2019
Completion
Feb 14, 2019
Last update
Feb 29, 2024

Study contacts

Michael S Kristensen, MD
principal investigator · Rigshospitalet, University Hospital of Copenhagen Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion